Revlimid (lenalidomide) does not fit neatly into either the chemotherapy or immunotherapy box. It belongs to a class of drugs called immunomodulatory imide drugs, commonly shortened to IMiDs, which work through a mechanism fundamentally different from both conventional chemotherapy and the newer immunotherapies like checkpoint inhibitors or CAR-T cells. Revlimid simultaneously boosts the immune system’s ability to attack cancer cells and directly kills cancer cells by hijacking one of the cell’s own protein-disposal systems. That dual nature is what makes its classification genuinely confusing, and why the honest answer is “neither, but also a bit of both.”
Why It Is Not Traditional Chemotherapy
Traditional chemotherapy drugs work by damaging DNA or disrupting cell division. They tend to kill any rapidly dividing cell, which is why they cause familiar side effects like hair loss, severe nausea, and widespread drops in blood counts. Revlimid does not operate this way. Rather than poisoning cells broadly, it redirects a specific protein-recycling machine inside the cell, an enzyme complex called cereblon, so that it tags certain proteins the cancer cell needs for survival. Those tagged proteins get sent to the cell’s internal shredder, the proteasome, and are destroyed. This mechanism, sometimes described as “molecular glue” degradation, is unlike anything in the traditional chemotherapy playbook.1PubMed Central. The novel mechanism of lenalidomide activity
There is also a practical difference that matters to patients. Revlimid is taken as a capsule at home, not infused in a clinic. A pilot study of older myeloma patients found that median adherence to oral lenalidomide was about 98%, suggesting most people manage the pill-based schedule well.2PubMed Central. A pilot study of adherence to lenalidomide among older patients with multiple myeloma That said, oral administration comes with its own challenges, including the need for consistent self-dosing, something that traditional infusion schedules handle by default.
The Protein Degradation Trick
At the molecular level, Revlimid’s central trick is changing what the cereblon enzyme complex decides to destroy. Normally, cereblon tags a set of proteins for disposal as part of routine housekeeping. When lenalidomide binds to cereblon, it alters the enzyme’s targeting so that it grabs proteins the cell would otherwise leave alone. In myeloma, the key targets are two transcription factors called IKZF1 and IKZF3 (also known as Ikaros and Aiolos). These proteins help myeloma cells survive and grow. Lenalidomide-bound cereblon marks them for destruction, and the myeloma cell loses critical survival signals.3PubMed Central. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
The downstream effects of eliminating IKZF1 and IKZF3 cascade through the myeloma cell. Two other proteins that myeloma cells depend on, IRF4 and MYC, drop in response, ultimately triggering cell death.4Blood. CXXC1 is required for IRF4 chromatin binding and expression and regulates cellular fitness in lenalidomide-sensitive and -resistant myeloma cells This is a direct anti-cancer effect. The drug is not simply waking up the immune system and hoping it handles the tumor; it is killing cancer cells on its own. That direct cytotoxic activity is the feature that makes Revlimid look most like chemotherapy, even though the underlying mechanism is completely different from DNA-damaging drugs.
How Revlimid Boosts the Immune System
The immunotherapy side of Revlimid is substantial and was actually recognized before the cereblon mechanism was fully understood. Lenalidomide stimulates T cells to proliferate and produce inflammatory signaling molecules. It also activates natural killer (NK) cells, which are a frontline defense against tumor cells. At the same time, it dials down certain inhibitory factors that cancers use to suppress the immune response.
Research in myeloma patients showed that lenalidomide treatment enhanced responses to a dendritic cell/myeloma fusion vaccine, increasing production of inflammatory cytokines and boosting the ability of immune cells to kill myeloma targets directly. The drug appeared to create a more favorable immune environment overall, promoting T-cell activity while suppressing the factors that normally let myeloma evade immune detection.5PubMed Central. Lenalidomide enhances anti-myeloma cellular immunity
Lenalidomide also has anti-angiogenic properties, meaning it inhibits the growth of new blood vessels that tumors need to sustain themselves. Animal studies showed that oral lenalidomide reduced blood-vessel formation in a dose-dependent manner and blocked endothelial cell migration, which is the process by which blood-vessel cells move to build new vessels.6PubMed. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Starving a tumor of its blood supply is yet another layer of activity that doesn’t fit the chemotherapy or immunotherapy label cleanly.
Taken together, lenalidomide acts as an immunomodulator across both the cellular and humoral branches of the immune system while simultaneously demonstrating anti-angiogenic and direct anti-tumor effects.7Journal of Hematology & Oncology. Mechanism of action of lenalidomide in hematological malignancies The breadth of activity across multiple pathways is part of what earned this drug class a name of its own rather than being folded into an existing category.
Enhancing Antibody Therapies
One of the most clinically useful immune effects of lenalidomide is its ability to make antibody-based therapies work better. When monoclonal antibodies like rituximab (used in lymphoma) or trastuzumab (used in breast cancer) coat a tumor cell, immune cells can recognize that coating and kill the cell through a process called antibody-dependent cellular cytotoxicity, or ADCC. Lenalidomide amplifies this process.
In laboratory studies, lenalidomide enhanced NK cell-mediated killing of rituximab-coated lymphoma cells, an effect that depended on the presence of the antibody and immune-stimulating signals.8Clinical Cancer Research. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells Similar results were observed with trastuzumab- and cetuximab-coated solid tumor cells, where lenalidomide boosted NK cell killing through interactions involving the NKG2D receptor on immune cells.9PubMed Central. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
This capacity to enhance antibody therapies is one reason lenalidomide features in so many combination regimens. It does not just add its own anti-cancer effects; it makes the immune-engaging therapies it’s paired with hit harder. In clinical practice, lenalidomide is commonly combined with dexamethasone (a steroid), proteasome inhibitors, and monoclonal antibodies in regimens for myeloma and lymphoma.
Different Diseases, Different Molecular Targets
A surprising aspect of lenalidomide is that it does not attack the same molecular target in every cancer. In multiple myeloma, the key victims of cereblon-mediated degradation are the IKZF1 and IKZF3 transcription factors described earlier. But in a specific type of myelodysplastic syndrome (MDS) where part of chromosome 5 is missing, known as del(5q) MDS, lenalidomide targets a different protein entirely: casein kinase 1 alpha (CK1α).
CK1α is encoded by a gene within the deleted region of chromosome 5. Because one copy of the gene is already gone, the remaining copy produces only half the normal amount of CK1α, and these cells are uniquely vulnerable when lenalidomide pushes cereblon to degrade even that reduced supply. Healthy cells with two working copies can tolerate some CK1α loss; the del(5q) cells cannot. This creates a therapeutic window where the drug selectively eliminates the abnormal cells.10PubMed Central. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
The fact that the same drug uses the same basic trick (redirecting cereblon) but hits different targets depending on the disease context is a key insight from lenalidomide research. It has also inspired a broader field of drug development aimed at designing molecules that redirect protein-disposal machinery to destroy previously “undruggable” targets.11PubMed Central. Cancer therapies based on targeted protein degradation – lessons learned with lenalidomide
Side Effects That Set It Apart From Chemo
If Revlimid were simply chemotherapy by another name, you would expect the classic chemotherapy side-effect profile: hair loss, constant vomiting, and devastated blood counts across the board. Revlimid’s side effects overlap with some of those but differ in character. The most common issues include low blood counts (particularly low neutrophils and low platelets), fatigue, diarrhea, and an increased risk of blood clots. Hair loss and severe nausea are not typical. Patients taking lenalidomide generally need blood-thinning medication to manage clot risk, which is not a standard part of chemotherapy management.
Because the drug is cleared primarily through the kidneys, dose adjustments are needed for patients with reduced kidney function. Pharmacokinetic modeling has confirmed that lower kidney filtration rates substantially affect how the body clears the drug.12PubMed Central. Population Pharmacokinetics and Model-Informed Precision Dosing of Lenalidomide Incorporating Total and Unbound Plasma Concentrations in Renally Impaired Patients with Multiple Myeloma This is relevant because many myeloma patients have kidney problems as a consequence of their disease.
Revlimid also carries a boxed warning for teratogenicity, inherited from its parent molecule thalidomide. Lenalidomide is structurally a modified version of thalidomide with greater potency and a different toxicity profile.13PubMed Central. Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma Because of the birth-defect risk, the drug is distributed only through a restricted program that requires pregnancy testing and contraceptive use.
The Secondary Cancer Risk
One side effect that genuinely concerns both patients and oncologists is the increased risk of developing a second, unrelated cancer during or after lenalidomide treatment. This risk is most clearly documented in the maintenance setting, where patients take lenalidomide for an extended period after initial treatment and stem-cell transplant to keep myeloma in remission.
In the CALGB 100104 trial, which followed 460 myeloma patients after transplant for a median of about seven and a half years, the cumulative incidence of blood-related secondary cancers was roughly 8% with lenalidomide maintenance compared to about 1% with placebo. The incidence of secondary solid tumors was about 6% versus 4%.14PubMed Central. Secondary Primary Malignancies in Multiple Myeloma: A Review Another trial, IFM 2005-02, was stopped early because of concern about the rate of second cancers. The Myeloma XI trial reported similar patterns: among transplant-eligible patients, the overall incidence of secondary cancers was roughly 8% with lenalidomide maintenance compared to about 3% with observation alone.15Blood. Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance
For most patients, the survival benefit of lenalidomide maintenance still outweighs this risk. But the elevated rates of second cancers mean that patients on long-term lenalidomide need ongoing monitoring with regular blood work and age-appropriate cancer screenings. The risk is something oncologists factor into the decision about how long maintenance therapy should continue.
Why the Label “Immunomodulatory Drug” Exists
The IMiD classification was created in part because drugs like lenalidomide genuinely do not belong in existing categories. Chemotherapy implies DNA-damaging or cell-division-blocking agents. Immunotherapy, in modern oncology, usually refers to drugs that release the brakes on the immune system (checkpoint inhibitors like nivolumab or pembrolizumab) or engineered immune cells (CAR-T therapy). Lenalidomide does something that overlaps with both but matches neither definition.
It kills tumor cells directly through targeted protein degradation, which resembles chemotherapy’s end result without its mechanism. It activates T cells and NK cells, which resembles immunotherapy’s end result without its mechanism. And it blocks blood-vessel growth, which resembles the mechanism of anti-angiogenic drugs like bevacizumab. The IMiD label acknowledges that this is a multi-pronged agent that defies a single-category assignment.
When patients or family members ask whether Revlimid is “chemo,” what they usually want to know is whether it will feel like chemotherapy: will there be infusions, hair loss, constant nausea, immune devastation? The practical answer is that Revlimid is milder than most traditional chemotherapy in those specific ways, though it brings its own distinct side-effect concerns. When the question comes from a scientific angle, the honest answer is that Revlimid straddles multiple categories and arguably launched a new one.
Where Revlimid Fits in Current Treatment
Lenalidomide was first approved in the United States in 2006 for use alongside dexamethasone in myeloma patients who had already received at least one prior therapy. Since then, its role has expanded considerably. It is now used as a front-line treatment for newly diagnosed myeloma, as long-term maintenance therapy after transplant, in del(5q) MDS, in certain lymphomas, and increasingly as part of multi-drug combinations that include proteasome inhibitors and monoclonal antibodies.
Its ability to enhance ADCC makes it a natural partner for antibody-based drugs, and its oral formulation makes it easier to incorporate into regimens that patients follow for months or years. The drug’s versatility across multiple cancers and treatment phases is unusual and stems directly from that multi-mechanism profile: in one setting, the immune-boosting effects may matter most; in another, the direct protein-degradation activity may be the primary driver of response.
The research that followed lenalidomide’s cereblon discovery has also reshaped drug development more broadly. The realization that a small molecule could redirect a protein-disposal enzyme to eliminate specific disease-driving targets has spawned an entire field of “targeted protein degradation” therapeutics. Dozens of experimental drugs now use similar molecular-glue or degrader approaches to go after proteins that were previously considered impossible to target with conventional drugs.11PubMed Central. Cancer therapies based on targeted protein degradation – lessons learned with lenalidomide In that sense, Revlimid is not just a treatment; it is a proof of concept that opened a new frontier in cancer pharmacology.